In cancer therapy, DNA-damaging agents have been shown to kill tumor cells by promoting p53-induced apoptosis, primarily by reducing the degradation of p53 [9, 10], and, to a lesser extent, by increasing the translation efficiency of p53 mRNA [11]. Here, TP53 is linked to neoplasm.